We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Photoacoustic Technology May Revolutionize Cancer Research

By LabMedica International staff writers
Posted on 13 Apr 2011
Innovative technology that combines the sensitivity of optical imaging with the resolution and depth penetration of high-frequency ultrasound will enable researchers to study cancer in its earliest stages of progression and evaluate tumor growth and the effect that potential drugs have on that growth.

The VisualSonics Inc. More...
(Toronto, Canada) Vevo LAZR uses a laser to shoot pulses of light through the skin into tissue and cells beneath the surface. The absorbed laser energy is then converted into heat, producing an ultrasonic emission, which can be captured and turned into images using a specially adapted high frequency ultrasonic probe. VisualSonics is a wholly owned subsidiary of SonoSite Inc. (Seattle, WA, USA).

The key to this novel approach is the capability of a wide range of biological materials to absorb laser light. Specific tissue components including oxyhemoglobin, deoxyhemoglobin, melanin, and lipids all absorb laser energy, which is then converted into heat that produces an ultrasonic emission that can be captured and turned into images using a specially adapted high frequency ultrasonic probe.

Applications for the Vevo LAZR system range from lymph node imaging to the study of hemoglobin and oxygen saturation and the targeted imaging of tumor biomarkers. In addition to cancer biology, this innovative technology will benefit other areas of life science research such as diabetes, neurosciences, and developmental and reproductive biology.

"The Vevo LAZR photoacoustics system is a breakthrough in vivo imaging technology,” said Anil Amlani president and CEO of VisualSonics. "Advancements featured in this product will enable oncology researchers to accelerate their research into understanding of the inner workings of the cancerous cell and the host tissue in which it resides. The ability to conduct this microscopic level research in a living organism, noninvasively and in real time will help our customers to turn groundbreaking science into lifesaving care, at an even greater speed.”

"We believe that the Vevo LAZR system will have a strong impact on the discovery of new cancer therapies, more efficient testing of therapies with never-before-seen insights into cancer, and quantified measures of cancer progression, viewed from inside the tumor,” said Kevin M. Goodwin, president and CEO of SonoSite. "With the launch of Vevo LAZR technology, we continue to meet our commitment to our customers by providing imaging technologies needed to further tomorrow's research today.”

Related Links:

VisualSonics Inc.
SonoSite Inc.



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.